Eisai Co., Ltd. to announce its first presentation with Merck & Co., Inc. associated with the Phase 3 LEAP-002 trial investigating LENVIMA, a receptor tyrosine, orally available and discovered by Eisai. Furthermore, the anti-PD-1 therapy, plus KEYTRUSA, from Merck & Co., Inc., is also introduced as a first-line treatment for uHCC.
SK Biopharmaceuticals Co., Ltd. to announce the result of the long-term randomized open-label extension (OLE). The company is focused on treatment development for central nervous system (CNS) disorders. Data analyzed in the OLE phase was taken from nearly 335 adult patients having focal seizures. from nearly 355 adult patients having focal seizures.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?